



## Antibiotic Treatment in Urinary Tract Infections (UTIs)

Guest Editor:

**Dr. Caroline Schneeberger**

Rijksinstituut voor  
Volksgezondheid en Milieu  
(RIVM), Antonie van  
Leeuwenhoeklaan 9, 3721 MA  
Bilthoven, The Netherlands

Deadline for manuscript  
submissions:

**closed (30 April 2023)**

### Message from the Guest Editor

Urinary tract infection (UTI) is one of the most common infections, assumed to be treated fairly easily and therefore not seen as a leading cause of preventable death. However, UTIs are getting more difficult or even impossible to treat due to increasing antimicrobial resistance (AMR). Alternative treatment strategies, both antibiotic and non-antibiotic options are needed.

Currently all over the world one is trying to develop new antibiotics and explore alternative applications of existing antibiotics. Moreover, one should investigate the possibilities for shorter antibiotic courses or “wait and see” strategies. As UTI is a common infection, only a slight decline in antibiotic use, can have substantial effects on the total antibiotic (selective) pressure and AMR.

The aim of this special issue is to update knowledge on antibiotic treatment strategies for UTI and to provide more insight into the AMR burden caused by UTI. Furthermore, we would like to provide a platform for novel ideas on how to reduce the total amount of antibiotics used to treat UTI.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1  
(*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)